Elliot M. Goldner

Prevalence and Incidence Studies of Anxiety Disorders: A Systematic Review of the Literature

This is the second in a series of papers that present systematic reviews of the prevalence and incidence of psychiatric disorders drawn from studies published in English literature in the years 1980 to 2000. The series discusses the implications of these epidemiologic findings to mental health policy and practice. Objective: To present the results of a systematic review of literature published between January 1, 1980, and December 31, 2000, that reports findings on the prevalence and incidence of mood disorders in both general population and primary care settings. Method: We conducted a literature search of epidemiologic studies of mood disorders, using Medline and HealthSTAR databases and canvassing English-language publications. Eligible publications were restricted to studies that examined subjects aged at least 15 years and over. We used a set of predetermined inclusion and exclusion criteria to identify relevant studies. We extracted and analyzed prevalence and incidence data for heterogeneity. Results: Of general population studies, a total of 18 prevalence and 5 incidence studies met eligibility criteria. We found heterogeneity across 1-year and lifetime prevalence of major depressive disorder (MDD), dysthymic disorder, and bipolar I disorder. The corresponding pooled rates for 1-year prevalence were 4.1 per 100, 2.0 per 100, and 0.72 per 100, respectively. For lifetime prevalence, the corresponding pooled rates were 6.7 per 100, 3.6 per 100, and 0.8 per 100, respectively. Significant variation was observed among 1-year incidence rates of MDD, with a corresponding pooled rate of 2.9 per 100. Conclusions: The prevalence of mood disorders reported in high-quality studies is generally lower than rates commonly reported in the general psychiatric literature. When controlled for common methodological confounds, variation in prevalence rates persists across studies and deserves continued study. Methodological variation among studies that have examined the prevalence of depression in primary health care services is so large that comparative analyses cannot be achieved.

Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature.

Objective: To present the results of a systematic review of the literature published between January 1, 1980, and December 31, 2000, that reports findings on the prevalence and incidence of schizophrenia and related disorders. Method: We conducted a literature search of schizophrenia-related epidemiological studies, using Medline and HealthSTAR databases and canvassing English-language publications. We used a set of predetermined inclusion-exclusion criteria to identify relevant studies. Eligible publications were restricted to age ranges of 18 years and over for prevalence studies and 15 years and over for incidence studies. Prevalence and incidence data were extracted and analyzed for heterogeneity. Results: A total of 18 prevalence and 8 incidence studies met eligibility criteria for the review. Heterogeneity analysis revealed significant differences across 1-year and lifetime prevalence and 1-year incidence of schizophrenia. The corresponding pooled rates were: 0.34 per 100, 0.55 per 100, and 11.1 per 100 000, respectively; the variation in rates between studies was generally between 2- and 5-fold. Conclusions: Although we restricted this review to studies using rigorous and relatively homogeneous methods, there remains significant heterogeneity of prevalence and incidence rates. This strengthens support for the hypothesis that there is real variation in the distribution of schizophrenia around the world. Health planners need to have local data on schizophrenia rates to improve the accuracy of their interventions, while clinicians and researchers need to continue to investigate the etiology of this variation.

Inhibited expression of negative emotions and interpersonal orientation in anorexia nervosa.

OBJECTIVE This study examined inhibited expression of negative feelings and interpersonal orientation in women with anorexia nervosa. METHOD Twenty-one women meeting DSM-IV criteria for anorexia nervosa were compared with 21 psychiatric and 21 normal control women matched on education. Two measures were used to assess inhibited expression of negative feelings and interpersonal orientation: the State-Trait Anger Expression Inventory assesses the suppression and expression of anger and the Silencing the Self Scale assesses four cognitive schemas involving the repression of needs and feelings to protect interpersonal relationships. RESULTS Women with anorexia nervosa reported significantly higher scores on the four Silencing the Self schemas and on suppressed anger after controlling for age. These group differences were maintained for two of the cognitive schemas (Care and Silence) after controlling for depression, self-esteem, and global assessment of functioning. Inhibited expression of negative emotion and interpersonal orientation scores were also significantly related to cognitive and affective components of body image dissatisfaction and to trait and self-presentational dimensions of perfectionism. DISCUSSION These findings are reviewed in the context of health psychology, as well as feminist and temperament theories. Implications for treatment are addressed.

Evidence-Based Psychiatry

Objective To apply the evidence-based medicine paradigm to the domain of psychiatric practice and to bring out the consequences for psychiatry of this approach in order to foster the emergence of an evidence-based psychiatry. Method The basic assumptions of traditional and evidence-based paradigms, as delineated by the Evidence-Based Working Group, are used to structure an exploration of the evidence-based approach to psychiatry. Theoretical and practical issues are considered and an example of evidence-based decision making is given. Results An evidence-based approach to psychiatry is described as one that emphasizes the importance of systematic observation and the use of rules of evidence in hypothesis testing. It is suggested that psychiatrists using this approach will be in a position to provide superior patient care. Discussion The application of scientific method to psychiatric problems is discussed as the essence of an evidence-based approach. The common error of “scientism” is described. The authors identify advantages and limitations of an evidence-based approach to psychiatric practice and advocate a decision-making process that balances individualized clinical acumen (phronesis) and information derived from empirical study of groups of patients (techne).

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.

The aim of this study was to evaluate the efficacy, tolerability, and effects on quality of life of sertraline, a selective serotonin reuptake inhibitor, in the prevention of relapse of generalized social phobia. Fifty adult outpatients with generalized social phobia who were rated much or very much improved on the Clinical Global Impression Scale of Improvement (CGI-I) after 20 weeks of sertraline treatment (50-200 mg/day) were randomly assigned in a one-to-one ratio to either continue double-blind treatment with sertraline or immediately switch to placebo for another 24 weeks. The initial 20-week study was placebo-controlled, and 15 responders to placebo also continued to receive double-blind placebo treatment in the continuation study. Eighty-eight percent of patients in the sertraline-continuation group and only 40% of patients in the placebo-switch and placebo-responder groups completed the study. In intent-to-treat endpoint analyses, 1 (4%) of 25 patients in the sertraline-continuation group and 9 (36%) of 25 patients in the placebo-switch group had relapsed at study endpoint (chi2 = 8.0, Fisher exact test, p = 0.01). The relative risk (hazards ratio) for relapse associated with placebo-switch relative to sertraline-continuation treatment was 10.2 (95% confidence interval, 1.3-80.7). Mean CGI-Severity, Marks Fear Questionnaire (MFQ) Social Phobia subscale, and Duke Brief Social Phobia Scale (BSPS) total scores were reduced by 0.07, 0.34, and 1.86 in the Sertraline-Continuation group and increased by 0.88, 4.09, and 5.99 in the Placebo-Switch group (all F > 5.3, p < 0.03), respectively. CGI-Severity, MFQ Social Phobia subscale, and BSPS scores also increased in the Placebo-Responder group. Discontinuations because of lack of efficacy were 4% in the sertraline-continuation group, 28% in the placebo-switch group (chi2 = 5.36, Fisher exact test, p = 0.049), relative to sertraline, and 27% in the placebo-responder group. Sertraline was effective in preventing relapse of generalized social phobia. Future research should assess whether improvements may be maintained or further increased by longer periods of treatment or through the addition of cognitive-behavioral techniques.

Shape- and weight-based self-esteem and the eating disorders

OBJECTIVES To determine the psychometric properties of the Shape- and Weight-Based Self-Esteem (SAWBS) Inventory in women with eating disorders, and to compare SAWBS scores in women who have eating disorders with women from psychiatric and normal control groups. METHOD Women with eating disorders (n = 48), women with other psychiatric disorders (n = 44), and undergraduate control women (n = 82) completed the SAWBS Inventory and measures of depression, self-esteem, and eating disorder symptomatology. Twenty women from the eating disorder group completed the SAWBS Inventory a second time 1 week later. RESULTS Similar to previous work in undergraduate samples, SAWBS scores were stable over 1 week, and demonstrated concurrent and discriminant validity in women with eating disorders. In between-group comparisons, SAWBS scores were higher among women with eating disorders than in either control group, even after controlling for age, socioeconomic status, body mass index, and self-esteem. A differing relationship between depression and SAWBS emerged as a function of group; SAWBS scores differed significantly among depressed, but not nondepressed women from the three groups. CONCLUSION The psychometric properties of the SAWBS Inventory were established in women with eating disorders. As expected, SAWBS scores were higher in women with eating disorders than in the control groups. Clinical implications of these findings are discussed.

Accuracy of subcutaneous fat measurement: Comparison of skinfold calipers, ultrasound, and computed tomography

OBJECTIVE The purpose of this study was to compare skinfold caliper and ultrasound measurement of subcutaneous body fat at three abdominal sites with computed tomography, which is considered to be the gold standard. DESIGN This was a cross-sectional study in which computed-tomography, ultrasound, and skinfold caliper measurements were made at three distinct abdominal sites. All body composition and anthropometric measurements were performed on each subject on one occasion. SUBJECTS Twenty-two subjects were recruited (13 men and 9 women). Mean ages (+/- standard deviation) were 43 +/- 4 years for the women and 51 +/- 18 years for the men. All subjects had been previously scheduled for an abdominal or pelvic computed-tomography scan at the Department of Radiology, St Pauls Hospital, Vancouver, British Columbia, Canada, and participated in the study on a volunteer basis. MAIN OUTCOME MEASURES A better agreement was found between the skinfold calipers and computed-tomography methods than between the ultrasound and computed-tomography method for the measurement of subcutaneous body fat. This was observed when the data were analyzed for both correlational agreement and for graphical interpretation. STATISTICAL ANALYSES PERFORMED The relationships among skinfold, ultrasound, and computed-tomography measurements were analyzed by determining Pearson correlation coefficients. A graphical method described by Bland and Altman was also used to assess agreement among the three methods. RESULTS Significant correlation coefficients were observed between skinfold calipers and computed tomography at all three abdominal sites (site 1, r = .60, P = .003; site 2, r = .70, P = .0001; site 3, r = .73, P = .0001). Ultrasound and computed-tomography methods only showed a significant correlation at site 3 (r = .54; P = .009). The graphical method revealed that the variation in the ultrasound measurements was much greater than that of the skinfold measurements when compared to computed-tomography values. APPLICATIONS/CONCLUSIONS The results of this study indicated that relative agreement in the measurement of subcutaneous body fat between skinfold and computed-tomography measurements was superior to that exhibited between ultrasound and computed-tomography measurements. This finding enhances the potential use of skinfold calipers in the clinical setting, particularly in view of the fact that measurement of subcutaneous body fat at different body sites is becoming increasingly important for the characterization of risk of certain disease states.

Anorexia nervosa: Refeeding and hypophosphatemia

A case of anorexia nervosa (AN) is reported where heart failure occurred secondary to severe hypophosphatemia despite oral phosphate supplementation. We recommend starting patients with AN on oral phosphate when refeeding is begun, monitoring serum phosphate every 1 to 2 days for at least the first week of refeeding, and discontinuation of refeeding during phosphate supplementation should severe hypophosphatemia develop.

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.

The purpose of this study was to evaluate the comparative efficacy and tolerability of sertraline and fluoxetine in the treatment of obsessivecompulsive disorder (OCD). Outpatients meeting DSM-IV criteria for OCD, with a Yale-Brown Obsessive-Compulsive (Y-BOCS) total score ≥ 17, an NIMH Global Obsessive-Compulsive (NIMH-OC) scale score ≥ 7, and a CGI-Severity score ≥ 4 were randomized to 24 weeks of double-blind treatment with sertraline (N = 77) or fluoxetine (N = 73). Primary efficacy measures consisted of the Y-BOCS, the NIMH-OC scale, and the CGI-Severity (CGI-S) and Improvement (CGI-I) scales. Equivalent and significant (p < 0.001) improvement was found at week 24 in Y-BOCS and NIMH-OC scale scores for sertraline and fluoxetine. After 12 weeks, 49.2% of patients on sertraline were rated on the CGI-S scale as being mildly ill or not ill compared to 24.6% on fluoxetine (p < 0.01). A Cox analysis found patients on sertraline to have a statistically nonsignificant 42% greater likelihood of achieving a response by week 12 (CGI-I, much or very much improved; 95% CI, 0.85, 2.38;p = 0.18). Sertraline treatment also resulted in a higher proportion of remissions than fluoxetine (defined as a CGI-I ≤ 2 and a Y-BOCS score ≤ 11), both at week 12 (20% vs. 8%; χ2, 3.95;df 1;p = 0.047) and week 24 (36% vs. 22%; χ2, 3.18;df, 1;p = 0.075). Both medications were welltolerated and demonstrated significant efficacy in the treatment of outpatients with moderate to severe OCD with the subjects treated with sertraline showing a greater likelihood of remission as well as an earlier improvement on some but not all efficacy measures

Treatment refusal in anorexia nervosa

Individuals with anorexia nervosa often refuse treatment for the disorder. A subset of individuals vehemently reject medical and/or psychological therapy. Of these some may be temporarily denied the right to refuse treatment. The author reviews psychological and philosophical aspects of treatment refusal by individuals with anorexia nervosa. Psychodynamic and cognitive processes involved in refusal are discussed. The author identifies principles which assist in guiding the negotiation of treatment refusal in anorexia nervosa.